Labile Copper Test Enhances Evaluation for Wilson's Disease: Joshua Bornhorst, Ph.D.
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Labile Copper Test Enhances Evaluation for Wilson's Disease: Joshua Bornhorst, Ph.D.
-
Narrated by:
-
By:
About this listen
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new test measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.
(00:32)
Can you tell us a little bit about yourself and your background?
(01:33)
Could you give us a brief overview of this assay?
(02:47)
Which patients should have this testing, and when should it be performed?
(03:48)
How would the results be used in patient care?
No reviews yet